THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS

THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS

The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atheroscleros...

Full description

Bibliographic Details
Main Authors:	O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova
Format:	Article
Language:	English
Published:	Столичная издательская компания 2018-07-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	atherosclerosis ischemic stroke ischemic heart disease lower-extremity arterial disease rosuvastatin acetylsalicylic acid fixed-dose combination clinical recommendations
Online Access:	https://www.rpcardio.online/jour/article/view/1699

Similar Items

New data on the use of rosuvastatin and acetylsalicyl acid for the prolongation of human life
by: M. V. Ezhov, et al.
Published: (2018-04-01)

Possibilities of using rosuvastatin to achieve target level of low-density lipoprotein cholesterol in clinical practice
by: Yuliia A. Prus, et al.
Published: (2020-03-01)

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects
by: Oh M, et al.
Published: (2019-04-01)

Acetylsalicylic acid in the prevention and treatment of ischemic stroke
by: A. V. Fonyakin
Published: (2010-06-01)

A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia
by: V I Podzolkov, et al.
Published: (2017-12-01)

Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects
by: Ryu H, et al.
Published: (2024-07-01)

RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA
by: N. F. Putchinyan, et al.
Published: (2015-12-01)

PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE
by: E. I. Tarlovskaya, et al.
Published: (2015-08-01)

Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy
by: I. A. Alekseeva, et al.
Published: (2019-10-01)

ROSUVASTATIN - THE MOST POTENT STATIN IN CARDIOVASCULAR DISEASE PREVENTION
by: A. E. Semenova, et al.
Published: (2018-06-01)

Psychological continuum of elderly hypertensive patients with metabolic syndrome receiving chronotherapy with a fixed-dose combination of amlodipine, lisinopril and rosuvastatin
by: N. M. Agarkov, et al.
Published: (2021-03-01)

THE INFLUENCE OF AUTOVENOUS ULTRAVIOLET IRRADIATION OF BLOOD SEPARATELY AND WITH ACETYLSALICYLIC ACID ON HEMOSTASIS STATE IN PATIENTS AFTER MYOCARDIAL INFARCTION
by: I. N. Rjamsina, et al.
Published: (2003-10-01)

Reducing cardiovascular risk: an emphasis on rosuvastatin
by: Anikin G.S., et al.
Published: (2017-11-01)

Modern possibilities of antihypertensive and lipid-lowering therapy in the treatment of comorbid patients with a very high risk of cardiovascular events
by: V. I. Podzolkov, et al.
Published: (2023-07-01)

COMBINED ACETYLSALICYLIC ACID TABLETS TECHNOLOGY
by: A. V. Simonyan, et al.
Published: (2019-01-01)

Combined treatment of dyslipoproteinemia in patients with atherosclerosis
by: K. K. Mirchuk
Published: (2017-06-01)

THE CONCERNS OF ROSUVASTATIN CLINICAL EFFICACY AND SAFETY
by: V. V. Kukharchuk, et al.
Published: (2013-06-01)

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
by: A. L. Khokhlov, et al.
Published: (2022-05-01)

Clinical pharmacology of acetylsalicylic acid as an anti-thrombotic agent
by: V. V. Rafalsky, et al.
Published: (1970-01-01)

Clinical evidences of low-dose rivaroxaban + acetylsalicylic acid treatment – who should be treated with dual pathway antithrombotic therapy?
by: Zoltán Járai
Published: (2024-04-01)

Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations
by: A. A. Sokolova, et al.
Published: (2023-12-01)

Rosuvastatin effects on systemic oxidative stress, endogenous inflammation and main neoangiogenesis factors in patients with atherosclerosis
by: Yu. V. Shchukin, et al.
Published: (2009-08-01)

Rosuvastatin safety and efficacy in coronary heart disease patients
by: I. V. Sergienko, et al.
Published: (2006-10-01)

The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis
by: I. S. Yavelov
Published: (2023-08-01)

Therapeutic Options for the Single Pill Combination of Lisinopril, Amlodipine and Rosuvastatin: a Systematic Review
by: S. R. Gilyarevsky, et al.
Published: (2022-09-01)

Compliance as the major effectiveness determinant in preventive acetylsalicylic acid therapy
by: V. V. Rafalskiy, et al.
Published: (2011-04-01)

Acetylsalicylic acid for the prevention of primary myocardial infarction and ischemic stroke
by: I V Samorodskaya, et al.
Published: (2015-09-01)

The problem of choice: original drug or generic? Emphasis on rosuvastatin
by: O. A. Polyakova, et al.
Published: (2022-05-01)

High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice
by: N. F. Puchinyan, et al.
Published: (2016-09-01)

ACETYLSALICYLIC ACID: DO WE KNOW EVERYTHING ABOUT IT AND ITS PROPER USE?
by: S. A. Boldueva, et al.
Published: (2015-12-01)

Use of acetylsalicylic acid and agronomic performance of potatoes in Lima region
by: Sergio Contreras-Liza, et al.
Published: (2022-04-01)

The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid
by: Jung Eun Kwon, et al.
Published: (2020-10-01)

Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat
by: Jasińska-Stroschein Magdalena, et al.
Published: (2014-09-01)

LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS?
by: I. V. Zhirov
Published: (2016-01-01)

Rosuvastatin-Induced reversible rhabdomyolysis
by: Sangeeta Pradhan, et al.
Published: (2023-01-01)

Rosuvastatin induced photolocalized purpura
by: Marwa Thabouti, et al.
Published: (2022-09-01)

Lipid metabolism disorders in patients with hypertension and diabetes mellitus: development and current treatment options
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

TRIPLE ANTIHYPERTENSIVE THERAPY: FOCUS ON EFFICACY AND PROGNOSIS
by: O. D. Ostroumova, et al.
Published: (2018-07-01)

Lipid-lowering and pleiotropic effects of rosuvastatin in patients with acute myocardial infarction
by: N. A. Dzhaiani, et al.
Published: (2008-12-01)

Acetylsalicylic acid (ASA) as inductor of growth and flowering in tomato
by: Artur Ascanio Almeida Barroso, et al.
Published: (2022-04-01)